Abstract
The use of doxorubicin (DOX) as a chemotherapeutic agent is limited by cardiac injury. Iloprost, a stable synthetic analogue of prostacyclin, has previously been shown to protect against DOX-induced cardiomyocyte injury in vitro. Here, we addressed whether iloprost is cardioprotective in vivo and whether it compromises the anti-tumour efficacy of DOX. Lewis Lung Carcinoma cells were implanted subcutaneously in the flank of C57BL/6 mice. DOX treatment was commenced from when tumours became visible. Iloprost was administered from prior to DOX treatment until sacrifice. Echocardiography and invasive haemodynamic measurements were performed immediately before sacrifice. As expected, DOX induced cardiac cell apoptosis and cardiac dysfunction, both of which were attenuated by iloprost. Also, iloprost alone had no effect on tumor growth and indeed, did not alter the DOX-induced suppression of this growth. In a murine model, iloprost attenuated the acute cardiac injury and dysfunction induced by DOX therapy without compromising its chemotherapeutic effect.
References
Dec 1, 1992·Biochemical Pharmacology·J CummingsJ F Smyth
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Jun 1, 1989·Cancer Metastasis Reviews
Oct 26, 1984·Science·K M TeweyL F Liu
Sep 1, 1996·The Journal of Clinical Investigation·H C YenD K St Clair
Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
Feb 13, 1999·The Journal of Biological Chemistry·S R Adderley, D J Fitzgerald
Oct 12, 1999·JAMA : the Journal of the American Medical Association·K M SheehanF E Murray
Jun 7, 2000·The Journal of Clinical Investigation·C S WilliamsR N DuBois
Aug 2, 2000·Circulation·T NakamuraE Koh
Feb 7, 2001·Circulation·S NegoroK Yamauchi-Takihara
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C MertensL L Robison
Oct 2, 2001·The Journal of Biological Chemistry·S V KalivendiB Kalyanaraman
Nov 14, 2001·Circulation·M G CamittaE Murphy
Feb 22, 2002·The Journal of Biological Chemistry·Srigiridhar KotamrajuB Kalyanaraman
Apr 3, 2002·The Journal of Biological Chemistry·Chuan-Ming HaoMatthew D Breyer
Apr 20, 2002·Science·Yan ChengGarret A FitzGerald
Sep 11, 2002·Circulation·Keisuke ShiojiJunji Yodoi
Nov 15, 2002·Cancer Letters·Shui-Tein ChenChun-Ming Huang
Jun 27, 2003·The Journal of Biological Chemistry·Kotha SubbaramaiahAndrew J Dannenberg
Oct 15, 2003·Circulation·Tian-li YueEliot H Ohlstein
Apr 1, 2004·The Journal of Biological Chemistry·Suwei WangB Kalyanaraman
Citations
May 25, 2013·Heart·Jeevan NagendranJason R B Dyck
Oct 24, 2009·Journal of Applied Physiology·Anna A BirukovaKonstantin G Birukov
Dec 6, 2006·Circulation·Christopher B Granger
Apr 25, 2013·Korean Circulation Journal·Sang-Ho JoYoung Jin Choi
Aug 20, 2009·Cardiology in Review·Kuldeep Maradia, Maya Guglin
Apr 14, 2006·European Heart Journal·Paul G HoranPascal P McKeown
Jun 24, 2011·Journal of Cardiovascular Pharmacology·Eva BarthaRobert Halmosi
Aug 13, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Alvaro MordenteElisabetta Meucci
Sep 14, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Merry L LindseyGregory J Aune
May 23, 2013·American Journal of Physiology. Endocrinology and Metabolism·Vernon W DolinskyJason R B Dyck
Oct 23, 2018·F1000Research·J Emanuel Finet, W H Wilson Tang
Jan 10, 2019·JACC. Basic to Translational Science·Albert Z LuuSubodh Verma
Sep 29, 2011·The Journal of Surgical Research·Michael ScullyAnthony J Cunningham
Jun 28, 2018·ACS Applied Materials & Interfaces·Yongzhi MenWuli Yang
Nov 28, 2012·Archives of Cardiovascular Diseases·Jean-Jacques Monsuez